International Journal of Medical and Pharmaceutical Research
2023, Volume-4, Issue-6 doi: 10.5281/zenodo.10453266
Original Article
Corelation of Giving Dha (Docosahexaenoic Acid) Supplements to Underweight Pregnant Women On Hba1c
 ,
 ,
Published
Dec. 31, 2023
Abstract

Background: Pregnancy is a physiological process in which the fetus develops in the body.  Where underweight pregnancies are those with a Body Mass Index of <18.5kg/m2.  In pregnant women there will be many changes in the systems in the body.  Apart from that, pregnant women need sufficient nutrition to consume.  Nutritional status in the body can be obtained and obtained from food intake, and apart from food intake, pregnant women also need additional nutrition in the form of macronutrients and micronutrients such as omega 3 fatty acids, namely DHA. This research aims to find out whether there is an influence  between HbA1c and DHA administration to pregnant women. 

Method: This research uses an experimental type of research with a cohort research design, using one group pretest-posttest. By providing treatment to pregnant women at community health centers who meet the inclusion and exclusion criteria. 

Results: Underweight pregnant women who were researched at the Made Surabaya Community Health Center with an age range of 21 to 36 years and a Body Mass Index ranging from 17.3 kg/m2 to 18.80 Kg/m2 were given supplementation in the form of DHA in this study. (Docosahexanoid acid) for one full month to be consumed by pregnant women. 

Conclusion: this study was that there was a decrease in HbA1c levels in underweight pregnant women

Recommended Articles
Loading Image...
Volume-4, Issue-6
Citations
2957 Views
361 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved